ORIGINAL ARTICLE

Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease

Arjun N. A. Jayaswal1 | Christina Levick2 | Emmanuel A. Selvaraj1,2,3 | Andrea Dennis4 | Jonathan C. Booth5 | Jane Collier2 | Jeremy Cobbold2 | Elizabeth M. Tunnicliffe1 | Matthew Kelly4 | Eleanor Barnes6 | Stefan Neubauer1 | Rajarshi Banerjee4 | Michael Pavlides1,2,3

Abstract

Background & Aims: Liver cT1, liver T1, transient elastography (TE) and blood-based biomarkers have independently been shown to predict clinical outcomes but have not been directly compared in a single cohort of patients. Our aim was to compare these tests’ prognostic value in a cohort of patients with compensated chronic liver disease.

Methods: Patients with unselected compensated liver disease aetiologies had baseline assessments and were followed up for development of clinical outcomes, blinded to the imaging results. The prognostic value of non-invasive liver tests at prespecified thresholds was assessed for a combined clinical endpoint comprising ascites, variceal bleeding, hepatic encephalopathy, hepatocellular carcinoma, liver transplantation and mortality.

Results: One hundred and ninety-seven patients (61% male) with median age of 54 years were followed up for 693 patient-years (median (IQR) 43 (26-58) months). The main diagnoses were NAFLD (41%), viral hepatitis (VH, 25%) and alcohol-related liver disease (ArLD; 14%). During follow-up 14 new clinical events, and 11 deaths occurred. Clinical outcomes were predicted by liver cT1 > 825ms with HR 9.9 (95% CI: 1.29-76.4, P = .007), TE > 8kPa with HR 7.8 (95% CI: 0.97-62.3, P = .02) and FIB-4 > 1.45 with HR 4.09 (95% CI: 0.90-18.4, P = .05). In analysis taking into account technical failure and unreliability, liver cT1 > 825 ms could predict clinical outcomes (P = .03), but TE > 8kPa could not (P = .4).

Conclusions: We provide further evidence that liver cT1, TE and serum-based biomarkers can predict clinical outcomes, but when taking into account technical failure/unreliability, TE cut-offs perform worse than those of cT1 and blood biomarkers.

KEYWORDS

1H-MRS, iron-corrected T1, Liver MultiScan, T1 mapping, T2* mapping
1 | BACKGROUND AND AIMS

Chronic liver diseases (CLDs) affect an estimated 1.5 billion people worldwide,¹ with the predominant causes being non-alcoholic fatty liver disease (NAFLD),² chronic viral hepatitis (VH) B and C³ and alcohol.⁴ Liver fibrosis is the final common pathway of injury in CLDs. Once fibrosis progresses to cirrhosis, each year approximately 5%-7% will become decompensated⁵ (develop variceal bleeding, ascites and hepatic encephalopathy). Cirrhosis is the 11th most common cause of mortality worldwide⁶ and liver cancer is reported as the 4th most common cause of cancer-related mortality.⁷

In the face of this public health epidemic there is an unmet clinical need to stratify disease severity in patients with CLD and to flag patients at risk of decompensation as early as possible. Liver biopsy is used routinely in clinical practice to assess fibrosis stage and inform prognosis,⁸ but is unsuitable for routine longitudinal follow-up of patients because of its invasive nature, associated risk and cost.

The magnetic resonance imaging (MRI) parameter T₁, when corrected for iron content (cT₁)⁹ can quantify extracellular water content, which rises with fibrosis and inflammation. Liver cT₁ correlates with liver fibrosis¹⁰ and severity of steatohepatitis,¹¹ has excellent repeatability and reproducibility¹² and is used in the UK Biobank population health study as the reference for liver fibroinflammatory disease.¹³ Liver cT₁, when stratified into groups according to a liver inflammation and fibrosis (LIF) score, was found to predict clinical outcomes in a general hepatology outpatient setting by Pavlides et al.¹⁴ Liver cT₁ is no longer converted into the LIF score and refinement of the algorithm used to generate liver cT₁ now enables it to be standardised across MRI scanner field strengths and vendors. Liver T₂ has also been shown to be associated with development of clinical outcomes in other cohorts.¹⁵,¹⁶

Transient elastography (TE) correlates with fibrosis¹⁷,¹⁸ and can predict clinical outcomes.¹⁹-²¹ Fibrosis-⁴ (FIB-⁴), aspartate aminotransferase to platelet ratio index (APRI) and AST/ALT ratio are commonly used markers of liver fibrosis/inflammation and have also been shown to predict clinical outcomes in patients with CLD.²²-²⁵ To date there has been no study evaluating the prognostic significance of MRI, TE and blood-based markers alongside histology as a reference.

Using a larger cohort of patients with CLD, over longer follow-up than Pavlides et al, the primary aim of this study was to assess the prognostic value of liver cT₁. Secondary aims were to assess the relative prognostic value of other liver-related biomarkers, including liver fat measured by MR proton spectroscopy (¹H-MRS), liver iron measured by T₂*h, transient elastography (TE), histological fibrosis stage and blood-based composite scores (FIB-⁴, APRI and AST/ALT ratio).

Table S1). Patients referred for a clinically indicated liver biopsy, or with a known diagnosis of liver cirrhosis, were eligible to take part. Patients were recruited from hepatology services in a teaching hospital and large district general hospital in the UK between May 2011 and July 2017. Patients with contraindications to MRI scanning were excluded. The studies were approved by the United Kingdom National Research Ethics Service (UK NRES references 13/SC/0243 and 11/H0504/2) and were conducted according to the declaration of Helsinki. All patients gave written and informed consent.

At baseline, patients underwent multiparametric MRI scans, TE and blood sampling following a minimum of 4 hours fasting.

2.2 | MRI protocol

All MRI scans were carried out at the University of Oxford Centre for Clinical Magnetic Resonance Research (OCMR) on a 3T Siemens Tim Trio scanner (Erlangen, Germany). Patients underwent the LiverMultiScan™ (Perspectum Diagnostics Ltd, Oxford, UK) acquisition protocol for T₁ and T₂* mapping and ¹H-MRS, as previously described.⁹,¹⁰

2.3 | MR Analysis

Spectroscopic data were fitted using the OXSA toolbox²⁶ implementation of the AMARES algorithm²⁷ with an in-house MATLAB (The Mathworks, Natick, MA, USA) script.²⁸ Liver fat fraction was calculated as the fat signal divided by the total fat and water signal.

LiverMultiScan™ is a software product, developed specifically to measure T₁, T₂* (iron content) and cT₁ (liver fibroinflammation), and was used for the image analysis in this study. Images were analysed.
by trained analysts blinded to the clinical and histological data (for details, see Supplementary methods; for example images, see Figure S1).

In previous publications,\textsuperscript{14} $cT_1$ was tri-linearly mapped to a discrete scoring system graded from 0 to 4 named the LIF score in an attempt to align with histological assessment gradations. The LIF score is no longer supported by LiverMultiScan\textsuperscript{TM}, and here we report $cT_1$ values.

### 2.4 | Histological assessment

All liver biopsies were performed as part of the patients’ clinical care using 18G needles for percutaneous biopsies and 19G needles for transjugular biopsies (quality and timing reported in Supplementary Information). All biopsies were included in the analysis as they were used to inform clinical care irrespective of the core length or number of portal tracts. All biopsies were assessed for the Ishak stage by a specialist liver histopathologist blinded to the imaging data. Fibrosis severity was defined as mild (Ishak F0-2), moderate (Ishak F3-4) and severe (Ishak F5-6).

### 2.5 | Blood samples

Blood samples were taken on the same day as the MRI scan. Simple scores for serum-based fibrosis markers Fibrosis-4 (FIB-4),\textsuperscript{29} aspartate aminotransferase/alanine aminotransferase (AST/ALT) ratio and AST to platelet ratio index (APRI)\textsuperscript{30} were calculated.

### 2.6 | Transient elastography (liver stiffness)

Transient elastography (TE) measurements of liver stiffness were performed using Fibroscan\textsuperscript{®} (Echosens, Paris) by trained operators with no prior experience. The M probe was used first and, if unable to obtain a measurement, the XL probe was then used. For a successful measurement, 10 valid readings were required and, as per recommended guidelines, unreliable readings were defined as having an IQR/median > 0.3, or success rate < 60%. Failure was defined as no measurement obtained using either M or XL probes.

### 2.7 | Clinical follow up

Outcome data were extracted from the patients’ electronic medical records. The primary clinical endpoint was a composite endpoint comprising ascites, variceal bleeding, hepatic encephalopathy, hepatocellular carcinoma (HCC), liver transplantation and mortality. A secondary endpoint was all-cause mortality. Patient records were reviewed by two researchers (blinded for review) blinded to the patients’ MRI and liver-related biomarker results until the patients’ latest medical evaluation, until they died, or were censored at 72 months maximum follow-up. Disagreements were adjudicated by a senior clinician (blinded for review). Patients were considered “lost to follow-up” if they did not return for any clinical follow-up after their baseline assessments. Where multiple events occurred, only the first event was counted in analysis. Patients were excluded if they had decompensated liver disease at baseline as a non-invasive liver test is unlikely to be needed in these patients.

### 2.8 | Statistical analysis

Baseline statistics are described as mean ± standard deviation (SD) for normally distributed variables and median (interquartile range [IQR]) for non-normally distributed variables. The primary outcome was survival of the composite endpoint, hereafter termed a ‘clinical event’. All-cause mortality was a secondary endpoint. Survival analysis was carried out on all the available data for each outcome with each biomarker, missing results were excluded from analysis and no imputation performed. Kaplan-Meier curves were compared using the log-rank test to evaluate significance of survival differences of binary and grouped cut-offs. All $p$ values quoted for binary cut-offs were calculated using the log-rank test. Cox proportional hazards analysis was used to calculate hazard ratios (HRs) for grouped and continuous variables. Where impossible to obtain a hazard ratio in cut-off analysis (because of zero events occurring in a group), sensitivity, specificity, positive predictive value (PPV) and negative predictive values (NPV) were reported. Receiver Operator Curve (ROC) analysis was performed for all continuous variables for the identification of patients who developed a new clinical event.

The primary variable of interest was liver $cT_1$. Cut-off values were predefined with $cT_1 > 825$ ms corresponding to the previously reported LIF score $\geq 2\textsuperscript{14}$ and the best (Youden index) cut-off was also assessed. Liver $cT_1$ was also grouped using the cut-offs corresponding to the 90% sensitivity and 90% specificity for identification of clinical events. To determine the importance of iron correction, we also assessed uncorrected liver $T_1^*$ at 825 ms and the best cut-off (Youden index) for prediction of events as there were no previously reported cut-offs at $3T$.

Secondary variables were liver iron as measured by $T_2^*$, liver fat as measured by $^1$H-MRS, liver stiffness as measured by TE, Ishak fibrosis stage, APRI, FIB-4 and AST/ALT. Cut-off values were chosen based on the literature (see Supplementary methods). Effect of treatment for underlying liver disease, presence of type 2 diabetes, body mass index (BMI) $>30$ kg/m$^2$ and age were also analysed for prediction of outcomes.

Given the spatial heterogeneity of disease often seen in autoimmune hepatitis (AIH) and biliary liver disease, which could affect the reliability of MRI and TE through sampling error, subgroup analysis was conducted for event-free survival in patients with only the 3 main liver disease aetiologies (NAFLD, ArLD and VH) where disease distribution is more homogenous.
To address the influence of technical rate of failure/unreliability of tests, separate intention to diagnose (ITD) analysis was conducted for event-free survival taking into account all attempted measurements, including technical failures and unreliable results. Unreliable results were included, and failed attempts were assigned either as false positive or false negative depending on the patient’s outcome, generating $3 \times 2$ tables (Table S2).

Non-invasive tests were assessed for event-free survival by multivariate Cox proportional hazards analysis in variables with sufficient data available.

Statistical significance was set at $P < .05$. Analysis was performed, and plots generated using R Statistical software.

3 \ | \ RESULTS

3.1 \ | \ Cohort characteristics

Two-hundred-and-thirty-five patients were included, of which 17 (7%) were lost to follow up and 21 (9%) were excluded for having decompensated liver disease at baseline (Figure 1). In total, 197 patients were followed up for a total of 693 patient-years with a median (IQR) follow-up of 43 (26-58) months.

Baseline characteristics for the whole cohort and for those who had/did not have clinical events are shown in Table 1. The three most common aetiologies of chronic liver disease were NAFLD ($n = 85$, 43%), ArLD ($n = 22$, 11%) and VH ($n = 50$, 25%). Overall, 178 (90%) patients had liver biopsy, in whom fibrosis was mild, moderate and severe in 95 (48%), 28 (14%) and 55 (28%) respectively. Fifty-nine patients had their underlying liver disease treated during the follow-up period—these included patients with chronic hepatitis C achieving a sustained virological response (SVR) ($n = 29$), patients with chronic hepatitis B achieving viral suppression ($n = 8$), patients regularly consuming harmful amounts of alcohol achieving complete abstinence ($n = 3$) and patients undergoing bariatric surgery who lost $> 10\%$ body weight ($n = 9$).

There were 14 new clinical events. Mortality occurred in 11 patients of which five patients died from non-liver-related causes (Table S3). Concordance of clinical event reporting between adjudicators was 93% (see Supplementary information for details).

Patients who had clinical events were older and had higher prevalence of ArLD, more severe fibrosis by histology and non-invasive biomarkers (serum scores, liver stiffness and liver $cT_1$), higher AST, ALP, GGT and bilirubin and lower albumin and platelets than patients without clinical events (Table 1).

3.2 \ | \ Survival analysis by biomarker

3.2.1 \ | \ Liver $cT_1$

3.2.1.1 \ | \ Whole cohort

MR scanning was successful in 182 of 197 (92%) patients, but failed in 15 (3 had claustrophobia, 1 did not fit in the scanner and 13 scans were of poor quality).

On univariate Cox regression, liver $cT_1$ had HR 1.007 (95% CI: 1.003-1.011, $P = .001$, Table S4) for event-free survival (0.7% increase in risk for every 1 ms increase in $cT_1$; equivalent to HR 1.91; 91% doubling of risk per 100 ms). Liver $cT_1$ had HR 1.007 (doubling of risk per 100 ms, 95% CI: 1.002-1.012, $P = .007$) for all-cause mortality.

The prespecified cut-off of liver $cT_1 > 825$ ms could predict event-free survival with HR 9.9 (95% CI: 1.29-76.2, $P = .007$) and all-cause mortality with HR 7.74 (95% CI: 0.98-61.2, $P = .02$, Figure 2A-B, Table S5). Liver $cT_1 > 825$ ms correctly identified 12/13 (92%) clinical events and 9/10 (90%) deaths.

The best cut-off for $cT_1$ was $> 840$ ms, which predicted event-free survival with HR 12.1 (95% CI: 1.57-93.1, $P = .002$, Figure 2C, Table S5) and all-cause mortality with HR 9.4 (95% CI: 1.19-74.2, $P = .01$).

FIGURE 1 \ Flow diagram of study
Liver cT₁ when stratified into groups showed significant increase in risk of clinical events with increasing cT₁ thresholds ($P < .001$, Figure 2D, Table S6).

In ITD analysis, liver cT₁ > 825 ms predicted event-free survival with HR 4.64 (95% CI: 1.04-20.8, $P = .03$) and cT₁ > 840ms with HR 5.57 (95% CI: 1.24-25.0, $P = .01$).

**TABLE 1** Baseline patient characteristics

|                                | All (n = 197) | Event free (n = 183) | With events (n = 14) | P value |
|--------------------------------|--------------|---------------------|---------------------|---------|
| Age (years)                    | 53 (44-59)   | 51 (44-59)          | 61 (57-69)          | .004    |
| Male                           | 123 (62)     | 112 (61)            | 11 (79)             | .198    |
| BMI (kg/m²)                    | 28.4 (24.8-34.0) | 28.4 (25.1-33.6) | 31.9 (24.7-34.8) | .528    |
| T2DM                           | 42 (21)      | 37 (20)             | 5 (36)              | .143    |
| Excess alcohol use             | 31 (16)      | 26 (14)             | 5 (36)              | .027    |
| Treatment during follow-up     | 59 (30)      | 56 (31)             | 3 (21)              | .472    |

Primary disease aetiology

|                                | Event free | With events | P value |
|--------------------------------|------------|-------------|---------|
| Viral hepatitis                | 50 (25)    | 47 (26)     | 3 (21.5) | .255    |
| NAFLD                          | 85 (43)    | 80 (44)     | 5 (36)  | .348    |
| ArLD                           | 22 (11)    | 19 (10)     | 3 (21.5) | .201    |
| PSC/PBC/AIH                    | 16 (8)     | 15 (8)      | 1 (7)   | .713    |
| Other*                         | 24 (13)    | 22 (12)     | 2 (14)  | .216    |

Histological fibrosis; Ishak stage

|                                | Event free | With events | P value |
|--------------------------------|------------|-------------|---------|
| Mild; F0-2                      | 95 (48)    | 93 (51)     | 2 (14)  | <.0001  |
| Moderate; F3-4                  | 28 (14)    | 28 (15)     | 0 (0)   |         |
| Severe; F5-6                    | 55 (28)    | 44 (24)     | 11 (79) |         |
| No biopsy                       | 19 (10)    | 18 (10)     | 1 (7)   |         |

Blood results

|                                | Event free | With events | P value |
|--------------------------------|------------|-------------|---------|
| ALT (IU/L)                     | 49 (30-92) | 51 (30-92)  | 46 (29-81) | .906    |
| AST (IU/L)                     | 41 (28-68) | 39 (28-66)  | 55 (45-90) | .013    |
| Albumin (g/L)                  | 44 (41-46) | 44 (42-47)  | 39 (35-44) | .0004   |
| ALP (IU/L)                     | 174 (130-238) | 170 (125-233) | 301 (178-406) | .0110   |
| Bilirubin (µmol/L)             | 11 (8-16)  | 10 (7-15)   | 24 (14-34) | .0003   |
| GGT (IU/L)                     | 72 (35-144) | 67 (33-122) | 345 (90-409) | .0013   |
| Platelets (x 10⁹ L)            | 196 (151-267) | 201 (155-269) | 105 (74-130) | .0005   |

Serum biomarkers

|                                | Event free | With events | P value |
|--------------------------------|------------|-------------|---------|
| FIB-4                          | 1.59 (0.92-2.69) | 1.51 (0.88-2.48) | 5.46 (4.25-10.45) | <.0001 |
| AST/ALT                        | 0.87 (0.60-1.17) | 0.83 (0.59-1.13) | 1.27 (1.16-1.79) | .0027 |
| APRI                           | 0.53 (0.31-0.95) | 0.50 (0.30-0.88) | 1.11 (0.92-2.18) | .0003 |
| Liver stiffness (kPa)           | 8.0 (5.6-14.6) | 7.8 (5.5-10.9) | 29.9 (15.1-35.3) | .0010 |
| Liver cT₁ (ms)                 | 840 (787-925) | 837 (786-923) | 901 (871-1068) | .0033 |
| Liver fat (%)                  | 4.90 (1.45-10.74) | 5.00 (1.43-10.88) | 4.28 (1.70-6.90) | .435 |
| T2* (ms)                       | 19.4 (14.0-22.5) | 19.2 (13.9-22.6) | 20.8 (18.4-21.1) | .495 |

Results shown are median (interquartile range) or n (%). P values quoted for the differences between patients with events and no events using the Wilcoxon non-parametric test.

Abbreviations: alanine aminotransferase, AST; alcohol-related liver disease, PSC; alkaline phosphatase, GGT; ALT; aspartate aminotransferase, ALP; AST-platelet ratio index, cT₁; autoimmune hepatitis; BMI; body mass index, T2DM; fibrosis-4 score, APRI; gamma-glutamyltransferase, FIB-4; iron-corrected T₁; non-alcoholic fatty liver disease, ArLD; primary biliary cholangitis, AIH; primary sclerosing cholangitis, PBC; type 2 diabetes mellitus, NAFLD.

*Other included cryptogenic cirrhosis, no specific features, sarcoid, cholestasis and haemochromatosis.
3.2.1.2 | NAFLD/ArLD/VH subgroup
In the NAFLD/ArLD/VH subgroup (n = 148), liver cT₁ predicted event-free survival with HR 1.007 (95% CI: 1.002-1.011, P = .005, Table S7).

Liver cT₁ > 825 ms predicted event-free survival (P = .006), identifying all 11 events (Figure 3A, Table S8). When stratified into groups, liver cT₁ showed significant increase in risk of clinical events with increasing cT₁ thresholds (P = .0048) (Figure 3B, Table S9).

In ITD analysis liver cT₁ > 825 ms could predict event-free survival (P = .009), identifying all events.

3.2.2 | Liver T₁
3.2.2.1 | Whole cohort
Uncorrected liver T₁ had HR 1.006 (P = .006, 95% CI: 1.002-1.01) for event-free survival and HR 1.007 (P = .007, 95% CI: 1.002-1.0011) for all-cause mortality.

Liver T₁ > 825 ms was not predictive of event-free survival (P = .08) or all-cause mortality (P = .06) and identified 10/13 (77%) clinical events correctly (Figure 4A, Table S5).

FIGURE 2 Kaplan-Meier plots for survival of clinical events stratified by liver cT₁. Plots show (A) survival from all-cause mortality, (B) event-free survival, each stratified by liver cT₁ > 825 ms, (C) event-free survival stratified by cT₁ > 840 ms and (D) event-free survival stratified by cT₁ groups (<840 ms, 840-990 ms and > 990 ms) in n = 182 patients with chronic liver disease. P values for differences between survival curves were generated by the log-rank test.
The best cut-off for liver $T_1$ was > 868 ms, which predicted event-free survival with HR 5.47 (95% CI: 1.50-20.0, $P = .004$, 10/13 (77%) events identified, Figure 4B, Table S5) and all-cause mortality with HR 7.2 (95% CI: 1.53-34.3, $P = .004$).

In ITD analysis ($n = 197$, 14 events) neither liver $T_1 > 825$ ms nor $T_1 > 868$ ms predicted event-free survival ($P = .2$ and 0.07 respectively).

3.2.2.2 | NAFLD/ArLD/VH subgroup

$T_1$ predicted event-free survival in the NAFLD/ArLD/VH subgroup with HR 1.005 (95% CI: 1.001-1.009, $P = .02$).

$T_1 > 825$ ms was unable to predict event-free survival in the NAFLD/ArLD/VH subgroup ($P = .09$, Figure 4A, Table S8). $T_1 > 868$ ms was able to predict event-free survival in the NAFLD/ArLD/VH subgroup with HR 6.17 (95% CI: 1.33-28.7, $P = .008$, Figure 4B) as well as in ITD analysis HR 5.32 (95% CI: 1.14-24.7, $P = .02$), identifying 9/11 (82%) events.

3.2.3 | Liver iron and liver fat

Neither liver iron nor liver fat was predictive of clinical outcomes in either the whole cohort or the subset of NAFLD/ArLD/VH (Tables S4, S5, S7 and S8).

3.2.4 | Histology

3.2.4.1 | Whole cohort

Biopsies were performed in 178/197 (90%) patients. In those with biopsy there were 13 clinical events and 11 deaths.

As a semi-continuous variable, Ishak stage could predict event-free survival with HR 1.99 between stages (95% CI: 1.32-3.01, $P = .001$, Table S10, Figure S2) and all-cause mortality with HR 1.82 (95% CI: 1.21-2.74, $P = .004$).

Ishak stage ≥ F5 predicted event-free survival with HR 12.6 (95% CI: 2.80-57.1, $P < .0001$, 11/13 (85%) events identified) and all-cause mortality with HR 9.75 (95% CI: 2.11-45.1, $P = .004$, 9/11 (82%) events identified).

When grouped into mild, moderate and severe fibrosis, Ishak stage showed an increase in risk of clinical events ($P = .002$, Table S10, Figure S2). Patients with moderate fibrosis showed no greater risk of clinical events than those with mild fibrosis.

3.2.4.2 | NAFLD/ArLD/VH subgroup

In the NAFLD/ArLD/VH subgroup ($n = 142$), Ishak stage could predict event-free survival ($P < .001$, Table S8).

Ishak fibrosis stage ≥ F5 was predictive of event-free survival ($P < .0001$), identifying 10/10 (100%) events.

3.2.5 | Transient elastography

3.2.5.1 | Whole cohort

TE was attempted in 160/197 (81%) patients with technical failure observed in 19 (12%). From the remaining 141 measurements, unreliable values were observed in 20 (14%) with 121 (76%) reliable TE measurements remaining.

TE predicted event-free survival with HR 1.062 (95% CI: 1.03-1.09, $P < .001$) and all-cause mortality with HR 1.069 (95% CI: 1.03-1.11, $P < .001$).

![Figure 3](Image)  
**Figure 3.** Kaplan-Meier plots for survival of clinical events stratified by liver $cT_1$ in a subset of patients with NAFLD, ArLD and viral hepatitis (VH). Patients ($n = 148$) were stratified by (A) liver $cT_1 > 825$ ms and (B) by $cT_1$ groups of $< 840$ ms, 840-930 ms and $> 930$ ms $P$ values for differences between survival curves were generated by the log-rank test.
TE > 8 kPa could predict all-cause mortality \((P = .008)\) identifying all deaths and event-free survival \((P = .02)\), identifying 8/9 (89%) clinical events.

When stratified into groups, TE showed significant increase in risk of clinical events with increasing TE thresholds \((P < .0001, \text{Table S11, Figure S3})\).

In ITD analysis, TE > 8 kPa could not predict event-free survival \((P = .4)\).

**3.2.5.2 | NAFLD/ArLD/VH subgroup**

In the NAFLD/ArLD/VH subgroup, TE was attempted in 126/157, failed in 14/126 (11%) and was unreliable in 15/112 (13%) (total failed and/or unreliable in 29/126 (23%).)

In the 97 patients with reliable measurements, TE predicted liver event-free survival with HR 1.083 (95% CI: 1.039-1.129, \(P < .001\)).

TE > 8 kPa was not predictive of event-free survival \((P = .06)\), identifying 6/7 (86%) events and not predictive of event-free survival in ITD analysis \((P = .5)\).

When stratified into groups, TE showed significant increase in risk of liver events with increasing TE thresholds \((P < .001, \text{Table S12})\).

**3.2.6 | Serum-based fibrosis markers**

**3.2.6.1 | Whole cohort**

FIB-4 predicted event-free survival with HR: 1.24 (95% CI: 1.15-1.34, \(P < .001\)) and all-cause mortality with HR 1.25 (95% CI: 1.14-1.37, \(P < .001\)). APRI did not predict event-free survival \((P = .8)\) nor all-cause mortality \((P = .995)\). AST/ALT ratio predicted event-free survival with HR 2.61 (95% CI: 1.61-4.21, \(P < .001\)) and all-cause mortality with HR 3.11 (95% CI: 1.79-5.40, \(P < .001\)).

FIB-4 > 1.45 predicted event-free survival with HR 4.11 (95% CI: 0.91-18.56, \(P = .05\)), 11/13 (85%) events identified, Figure S4).

APRI > 1 did not predict event-free survival \((P = .07)\). AST/ALT ratio > 1 predicted event-free survival with HR 6.09 (95% CI: 1.67-22.2, \(P = .002\)), 10/13 (77%) events identified, Figure S5).

ITD analysis results were exactly the same as there were no failed tests.

**3.2.6.2 | NAFLD/ArLD/VH subgroup**

In the patients with serum blood tests available, there were \(n = 148\), with 11 clinical events occurring.

FIB-4 could all predict event-free survival with HR 1.52 (95% CI: 1.29-1.79, \(P < .001\)). APRI could predict event-free survival with HR 1.93 (95% CI: 1.35-2.75, \(P < .001\)). AST/ALT ratio could predict event-free survival with HR 3.34 (95% CI: 1.97-5.68, \(P < .001\)).

FIB-4 > 1.45 could predict event-free survival with HR 7.08 (95% CI: 0.90-56, \(P = .03\), 9/10 (90%) events identified, APRI > 1 could predict event-free survival with HR 4.37 (95% CI: 1.23-15.6, \(P = .01\), 6/10 (60%) events identified) and AST/ALT > 1 could predict event-free survival with HR 18.3 (95% CI: 2.32-144, \(P < .001\), 9/10 (90%) events identified).

The details of the intention to diagnose analysis for all biomarkers are included in the supplement (Tables S13–S19).

**3.2.7 | Traditional risk factors**

Age was predictive of event-free survival \((P = .008, \text{HR: 1.073, 95\% CI: 1.02-1.13})\) and all-cause mortality \((\text{HR 1.08, 95\% CI: 1.02-1.15, } P = .02)\). Neither presence of type 2 diabetes nor BMI > 30 kg/m\(^2\)}
nor treatment for underlying liver disease was predictive of event-free survival or all-cause mortality.

3.3 | Multivariate analysis

TE was excluded as a result of insufficient quantity of data. No more than two variables were assessed together because of the low number of events per variable (EPV).

3.3.1 | Continuous variables

Liver $cT_1$ showed a trend towards being predictive of event-free survival independently of liver $T_1$. Liver $cT_1$ was predictive of event-free survival independently of APRI score. Liver $cT_1$ was not predictive of event-free survival independently of either FIB-4 or AST/ALT ratio, (Table 2). Liver $cT_1$ was predictive of event-free survival independently of Age (Table S20).

3.3.2 | Binary cut-offs

Liver $cT_1 > 825$ ms was predictive of event-free survival independently of $T_1 > 825$ ms. Liver $cT_1 > 825$ ms was predictive of event-free survival independently of FIB-4 > 1.45 and AST/ALT > 1 but not APRI > 1, (Table 3).

All multivariate analysis results should be taken with caution as EPV varied between 6 and 7 rather than the recommended 10.

### TABLE 2

Cox proportional hazards multivariate analysis for event-free survival—continuous variables

| Variable          | Hazard ratio | 95% CI      | P value | Number of observations and events |
|-------------------|--------------|-------------|---------|-----------------------------------|
| Liver $cT_1$ and $T_1$ |              |             |         |                                   |
| $cT_1$            | 1.0072       | 1.00-1.015  | .053    | 182 observations, 13 events       |
| $T_1$             | 0.9996       | 0.99-1.006  | .897    |                                   |
| Cox model         | -            | -           | .004    |                                   |
| Liver $cT_1$ and APRI  |              |             |         |                                   |
| $cT_1$            | 1.0057       | 1.001-1.010 | .010    | 172 observations, 12 events       |
| APRI              | 0.9977       | 0.926-1.08  | .953    |                                   |
| Cox model         | -            | -           | .03     |                                   |
| Liver $cT_1$ and FIB-4 |              |             |         |                                   |
| $cT_1$            | 1.004        | 0.998-1.009 | .215    | 171 observations, 12 events       |
| FIB-4             | 1.390        | 1.19-1.62   | <.0001  |                                   |
| Cox model         | -            | -           | <.0001  |                                   |
| Liver $cT_1$ and AST/ALT |           |             |         |                                   |
| $cT_1$            | 1.004        | 1.000-1.008 | .065    | 173 observations, 12 events       |
| AST/ALT           | 2.267        | 1.34-3.85   | .002    |                                   |
| Cox model         | -            | -           | <.0001  |                                   |

4 | DISCUSSION

We have shown further evidence with 693 patient-years of follow-up that liver $cT_1$ can predict all-cause mortality and event-free survival. The prognostic values of uncorrected liver $T_1$, TE, Ishak fibrosis stage and blood-based markers of liver disease severity were also assessed in the same cohort. Liver $cT_1 > 825$ ms correctly identified 12/13 (92%) of clinical events and performed even better when the patient cohort was restricted to NAFLD, ArLD and VH, identifying all liver events.

Higher liver $T_1$ has been shown in a previous study to be associated with the development of liver-related clinical outcomes, albeit in a cohort of patients with CLD with normal liver iron content. In our study there were two patients correctly indentified by liver $cT_1 > 825$ ms who developed liver events who were missed by uncorrected $T_1 > 825$ ms This reduced the correct classification percentage from 92% to 77%. The best $T_1$ cut-off was > 868 ms, which could not predict clinical events in ITD analysis, whereas $cT_1$’s best cut-off of > 840 ms could. As liver iron content itself (as measured by MRI $T_2^*$) was not predictive of clinical outcomes, these results underscore the utility of the iron correction method. This is especially important given the prevalence of elevated liver iron content in the general population and in patients with ArLD and NAFLD.

Although excess liver fat can accelerate fibrosis progression in certain patients, our results showed no association of liver fat with clinical outcomes. This supports other studies that have shown histological liver fibrosis is the only parameter independently associated with poorer outcomes.
In comparison to Ishak fibrosis stage F5-6, which could identify 11/13 (85%) of clinical events, cT1 > 825 ms identified 12/13 (92%) events. Liver cT1 > 825 ms also had a similarly high NPV to biopsy for the exclusion of patients with events (99% vs 98%), indicating its suitability as a screening test. Here, liver cT1 but not TE at their respective prespecified cut-offs could predict event-free survival—this is likely because of the lower number of events assessed by reliable TE results, as on univariate analysis TE was strongly predictive of developing clinical events. Additionally, when failed/unreliable results were accounted for, TE > 8 kPa was unable to predict liver event-free survival, whereas liver cT1 > 825 ms could. This was a true intention-to-diagnose analysis as there were no data collected on patients excluded at the outset as a result of MRI contraindications, therefore, the success rates of MRI and TE in the general CLD population may be different. Our reported TE failure rates are comparable to studies in NAFLD, but higher than in other prognostic studies conducted in cohorts with no or smaller (<13.5%) proportions of NAFLD patients. Our cohort contained a significant proportion (43%) of NAFLD patients (including patients scheduled for bariatric surgery), in which it is reported that TE performs less well and can reach failure/unreliability rates of 20%. This is an important consideration with NAFLD now the most prevalent CLD. The inexperience of the operators may have influenced the high failure/unreliability rate, as has been reported in previous studies. A distinct advantage of cT1, therefore, is its technical success rate, also reported as 98% vs 85% for TE in a study including patients with obesity and ascites. In our study, liver cT1 failed mainly in those who either were unable to enter the scanner (claustrophobia) or with extremely high iron (haemochromatosis), degrading the T2* signal. Liver cT1 also has excellent test-retest repeatability and reproducibility metrics compared with a high coefficient of variation for TE. In clinical practice, if a TE measurement is unreliable/fails, patients are often biopsied. Liver cT1 would be a useful diagnostic alternative to TE—or as a second-line test after TE in failed cases—to avoid unnecessary biopsies. Liver cT1 will perhaps be most useful in NAFLD/ArLD/VH where we have shown it has the most prognostic value and has been shown in other studies to be cost-effective in the non-invasive risk stratification and diagnostic pathway of NAFLD.

In this study, the serum-based composite biomarkers FIB-4 performed well overall with AST/ALT performing well in the subset of patients with NAFLD/ArLD/VH. FIB-4 has performed well in tertiary care settings, often performing better in patients with hepatitis C than NAFLD/ArLD. AST/ALT ratio's prognostic ability has also been limited to few studies in patients with viral hepatitis, so its excellent performance here must be taken in context of those results. Blood tests are cheap, easily repeatable and not susceptible to 'technical failure'. However, guidelines suggest that they should not be used in isolation as a result of their reduced specificity for liver disease but should be combined with other modalities. Liver cT1 is likely to have a greater impact earlier rather than later in the screening process for the detection of early liver fibroinflammatory disease and help in monitoring these patients non-invasively. Studies of even larger cohorts may bring out these differences in the future.

We have shown liver cT1 performs especially well in the most prevalent CLDs, namely, NAFLD, ArLD and VH, with cT1 cut-offs correctly identifying all liver events. These particular diseases represent a significant financial cost to the UK’s social and healthcare systems. Accurate, cost-effective stratification of these patients with non-invasive biomarkers would allow significant savings in time and money and an increase in patient comfort. There is also an unmet need for reliable

### Table 3 Cox proportional hazards multivariate analysis for event-free survival—binary cut-offs

|                | Hazard ratio | 95% CI | P value | Number of observations and events |
|----------------|--------------|--------|---------|-----------------------------------|
| Liver cT1 > 825 ms and T1 > 825 ms |             |        |         |                                   |
| cT1 > 825 ms  | 18.6         | 1.73-199 | .016   | 182 observations, 13 events       |
| T1 > 825 ms   | 0.47         | 0.10-2.12 | .327   |                                   |
| Cox model     | --           | --      | .01     |                                   |
| Liver cT1 > 825 ms and APRI > 1 |             |        |         |                                   |
| cT1 > 825 ms  | 7.7          | 0.97-61.7 | .054   | 172 observations, 12 events       |
| APRI > 1      | 2.1          | 0.65-6.60 | .215   |                                   |
| Cox model     | --           | --      | .01     |                                   |
| Liver cT1 > 825 ms and FIB-4 > 1.45 |             |        |         |                                   |
| cT1 > 825 ms  | 8.1          | 1.04-63 | .046   | 171 observations, 12 events       |
| FIB-4 > 1.45  | 2.9          | 0.63-13 | .171   |                                   |
| Cox model     | --           | --      | .01     |                                   |
| Liver cT1 > 825 ms and AST/ALT > 1 |             |        |         |                                   |
| cT1 > 825 ms  | 10.7         | 1.4-83  | .023   | 173 observations, 12 events       |
| AST/ALT > 1   | 9.7          | 2.1-44  | .003   |                                   |
| Cox model     | --           | --      | <.0001  |                                   |
non-invasive endpoints in NASH drug development. Liver cT1 can differentiate simple steatosis from NASH, and the prognostic value of liver cT1 shown in this study provides further evidence to support the use of liver cT1 for prognostic enrichment in NASH drug trials.

We conducted multivariate analysis which indicated liver cT1 to perform as well as T1c, better than APRI, but worse than FIB-4 and AST/ALT. However, analysis also showed that at the prespecified cut-offs, liver cT1 performed better than T1c and FIB-4 and similarly to AST/ALT and APRI. Meaningful cut-offs are desirable in clinical use, indicating liver cT1 has independent clinical prognostic relevance. These multivariate results should be taken with caution as the number of events per variable was lower than the minimum recommended threshold and therefore may yield results with high margin of error.

Limitations of this study included no fixed follow-up time point. This means that the AUC analyses, sensitivities, specificities, PPVs and NPVs generated in cut-off analysis should be taken with caution because unlike in Cox proportional hazards and Kaplan-Meier analysis, the effect of patients being censored at different time points is not taken into account. Our patient cohort included a wide range of liver disease severity and aetiologies from patients with mild fibrosis to those with cirrhosis. Future studies should examine the prognostic value of liver cT1 alongside other non-invasive tests in prespecified liver disease severity groups.

In conclusion, liver iron-corrected T1 (cT1), TE and serum-based blood biomarkers can identify patients at risk of developing clinical outcomes in a cohort with mixed CLD aetiologies, typical of general hepatology cohorts, but when taking into account technical failures of MRI and TE, MRI and blood markers perform better than TE. Further multicentre studies should be carried out to validate our results.

CONFLICTS OF INTEREST
ANAJ, EMT, MK, EB, SN, RB and MP are shareholders in Perspectum Ltd. RB is on the board of directors of Perspectum. RB, AD and MK are employees of Perspectum. EMT, EB, SN, RB and MP have filed patent applications related to the use of MRI for the assessment of liver disease. CL, EAS, JCB, JC, JC and EAS have nothing to declare.

AUTHORS’ CONTRIBUTIONS
MP, RB, SN and EB designed the study. ANAJ and EAS collected outcome data. EMT developed the iron correction method. ANAJ and AD performed the statistical analysis. CL, RB, JCB, JC, JB, EB and MP recruited patients to the study. ANAJ, CL, MK, SN, EB, RB and MP drafted the manuscript. All authors reviewed the manuscript critically and have approved the final version.

ORCID
Arjun N. A. Jayaswal  https://orcid.org/0000-0002-3272-2695
Michael Pavlides  https://orcid.org/0000-0001-9882-8874

REFERENCES
1. James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1789-1858.
2. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84.
3. World Health Organization. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017; Licence: CC BY-NC-SA 3.0 IGO. WHO. 2017. https://doi.org/10.1149/2.03020jhes
4. World Health Organization. Global status report on alcohol and health 2018. Geneva: World Health Organization; 2018. Licence: CC BY-NC-SA 3.0 IGO. (2018).
5. D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217-231.
6. World Health Organization. Global Health Estimates 2016: Disease burden by Cause, Age, Sex, by Country and by Region, 2000–2015. 2018.
7. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
8. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397.e10.
9. Tunnicliffe EM, Banerjee R, Pavlides M, Neubauer S, Robson MD. A model for hepatic fibrosis: the competing effects of cell loss and iron on shortened modified Look-Locker inversion recovery T1(shMOLLI-T1) in the liver. J Magn Reson Imaging 2017;45:450-462.
10. Banerjee R, Pavlides M, Tunnicliffe EM, et al. Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol. 2014;60:69-77.
11. Pavlides M, Banerjee R, Tunnicliffe EM, et al. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity. Liver Int. 2017;37:1065-1073.
12. Bachtiar V, Kelly MD, Wilman HR, et al. Repeatability and reproducibility of multiparametric magnetic resonance imaging of the liver. PLoS One. 2019;14:e0214921.
13. Mojtahed A, Kelly CJ, Herlihy AH, et al. Reference range of liver corrected T1 values in a population at low risk for fatty liver disease—a UK Biobank sub-study, with an appendix of interesting cases. Abdom Radiol. 2018;44:72-84.
14. Pavlides M, Banerjee R, Sellwood J, et al. Multiparametric magnetic resonance imaging predicts liver-related complications and mortality in patients with chronic liver disease. J Hepatol. 2016;64:308-315.
15. Bradley CR, Cox EF, Scott RA, et al. Multi-organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging. J Hepatol. 2018;69:1015-1024.
16. Ostovanerh MR, et al. Association of liver fibrosis with cardiovascular diseases in the general population: the Multi-Ethnic Study of Atherosclerosis (MESA). Circ Cardiovasc Imaging. 2018;11:1-10.
17. Friedrich–Rust M, Ong M, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology. 2008;134:960-974.
18. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156:1717-1730.
19. Pang JXQ, Zimmer S, Niu S, et al. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One. 2014;9:e95776.
20. Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140:1970-1979.e3.
21. Klöbansky DA, Mehta SH, Curry M, et al. Transient elastography for predicting clinical outcomes in patients with chronic liver disease. J Viral Hepat. 2012;19:e184-e193.

22. Bourrier J, et al. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. J. Hepatol. 2016;65:570-578.

23. Bourrier J, Brochard C, Bertrais S, et al. Combination of blood tests for significant fibrosis and cirrhosis improves the assessment of liver-prognosis in chronic hepatitis C. Aliment Pharmacol Ther. 2014;40:178-188.

24. Naveau S, Gaudé G, Asnacios A, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology. 2009;49:97-105.

25. Giannini E, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163:218.

26. Purvis LAB, Clarke WT, Biasiolli L, et al. OXSA: An open-source magnetic resonance spectroscopy analysis toolbox in MATLAB. PLoS One. 2017;12.

27. Vanhamme L, van den Boogaart A, Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129:35-43.

28. Rial B, Robson MD, Neubauer S, Schneider JE. Rapid quantification of myocardial lipid content in humans using single breath-hold 1H MRS at 3 Tesla. Magn Reson Med. 2011;66:619-624.

29. Sterling RK, Lissen E, Clumeeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-1325.

30. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatol. 2003;38:518-526.

31. Schuetz GM, Schlattmann P, Dewey M. Use of 3×2 tables with an intention to diagnose approach to assess clinical performance of diagnostic tests: Meta-analytical evaluation of coronary CT angiography studies. BMJ. 2012;345:1-10.

32. R Core Team. R: A language and environment for statistical computing. 2018.

33. McKay A, Wilman HR, Dennis A, et al. Measurement of liver iron by magnetic resonance imaging in the UK Biobank population. PloS One. 2018;13:e0209340.

34. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejståhl R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J. Hepatol. 2002;37:837-842.

35. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828-835.

36. Ketkaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol. 2007;46:628-634.

37. McDonald N, Eddowes PJ, Hodson J, et al. Multiparametric magnetic resonance imaging for quantification of liver disease: a two-centre cross-sectional observational study. Sci Rep. 2018;8:9189.

38. Harrison SA, Dennis A, Fiore MM, et al. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PLoS One. 2018;13:e0203054.

39. Eddowes PJ, McDonald N, Davies N, et al. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47:631-644.

40. Blake L, Duarte RV, Cummins C. Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging. BMJ Open. 2016;6:e010507.

41. Sebastiani G, Alshaalan R, Wong P, et al. Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure Gradient (HVPG) and histology in nonalcoholic steatohepatitis. PLoS One. 2015;10:e0128774.

42. Nunes D, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol. 2010;105:1346-1353.

43. Schuetz GM, Schlattmann P, Dewey M. Use of 3×2 tables with an intention to diagnose approach to assess clinical performance of diagnostic tests: Meta-analytical evaluation of coronary CT angiography studies. BMJ. 2012;345:1-10.

44. R Core Team. R: A language and environment for statistical computing. 2018.

45. Foundation for Liver Research. Financial case for action on liver disease. 2017.

46. Eddowes PJ, McDonald N, Davies N, et al. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47:631-644.

47. Eddowes PJ, McDonald N, Davies N, et al. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47:631-644.

48. Blake L, Duarte RV, Cummins C. Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging. BMJ Open. 2016;6:e010507.

49. Sebastiani G, Alshaalan R, Wong P, et al. Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure Gradient (HVPG) and histology in nonalcoholic steatohepatitis. PLoS One. 2015;10:e0128774.

50. Nunes D, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol. 2010;105:1346-1353.

51. Schuetz GM, Schlattmann P, Dewey M. Use of 3×2 tables with an intention to diagnose approach to assess clinical performance of diagnostic tests: Meta-analytical evaluation of coronary CT angiography studies. BMJ. 2012;345:1-10.

52. R Core Team. R: A language and environment for statistical computing. 2018.

53. Westin J, Nordlinder H, Lagging M, Norkrans G, Wejståhl R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J. Hepatol. 2002;37:837-842.

54. Castéra L, Foucher J, Bernard PH, et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology. 2010;51:828-835.

55. Ketkaneh A, Marcellin P, Douvin C, et al. Features associated with success rate and performance of fibroscan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol. 2007;46:628-634.

56. McDonald N, Eddowes PJ, Hodson J, et al. Multiparametric magnetic resonance imaging for quantification of liver disease: a two-centre cross-sectional observational study. Sci Rep. 2018;8:9189.

57. Harrison SA, Dennis A, Fiore MM, et al. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial. PLoS One. 2018;13:e0203054.

58. Eddowes PJ, McDonald N, Davies N, et al. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2018;47:631-644.

59. Blake L, Duarte RV, Cummins C. Decision analytic model of the diagnostic pathways for patients with suspected non-alcoholic fatty liver disease using non-invasive transient elastography and multiparametric magnetic resonance imaging. BMJ Open. 2016;6:e010507.

60. Sebastiani G, Alshaalan R, Wong P, et al. Prognostic value of non-invasive fibrosis and steatosis tools, hepatic venous pressure Gradient (HVPG) and histology in nonalcoholic steatohepatitis. PLoS One. 2015;10:e0128774.

61. Nunes D, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol. 2010;105:1346-1353.

62. Schuetz GM, Schlattmann P, Dewey M. Use of 3×2 tables with an intention to diagnose approach to assess clinical performance of diagnostic tests: Meta-analytical evaluation of coronary CT angiography studies. BMJ. 2012;345:1-10.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Jayaswal ANA, Levick C, Selvaraj EA, et al. Prognostic value of multiparametric magnetic resonance imaging, transient elastography and blood-based fibrosis markers in patients with chronic liver disease. Liver Int. 2020;40:3071–3082. https://doi.org/10.1111/liv.14625